Alpha Tau Medical Ltd Dossier
Qualitative Analysis
Business overview
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a clinical-stage oncology therapeutics company founded in 2015 and headquartered in Jerusalem, Israel. The company is dedicated to the research, development, and commercialization of Diffusing Alpha-emitters Radiation Therapy (Alpha DaRTu0000) for the treatment of solid tumors. Alpha DaRT represents a paradigm shift in localized radiation therapy, utilizing intratumoral delivery of radium-224 impregnated sources. As the radium decays, it releases short-lived alpha-emitting isotopes that diffuse throughout the tumor, delivering highly potent, conformal alpha-radiation that destroys cancer cells with sub-millimeter precision while sparing surrounding healthy tissue. The company's technology is being evaluated across multiple clinical applications globally, including skin, oral cavity, pancreatic, prostate, breast, and brain cancers.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out and operationalizing the commercial-scale manufacturing facility in Hudson, New Hampshire, following the receipt of its radioactive material license.
Expected impact: Establish local production capacity of approximately 400,000 Alpha DaRT sources in the first phase of construction to support clinical and commercial demand in the U.S.
Advancing five parallel clinical trials in the United States (cSCC, pancreatic, glioblastoma, prostate, and immunocompromised cSCC) and exploring a sixth trial combining Alpha DaRT with checkpoint inhibitors.
Expected impact: Broaden the therapeutic indications of the Alpha DaRT platform across multiple solid tumor types.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborate on the development and commercialization of Alpha DaRT for the treatment of prostate cancer in the U.S., leveraging Tolmar's established presence in the urological oncology field.
Terms: $20 million equity investment in Alpha Tau at $11.99 per share, $15 million towards the construction of a new production facility, up to $96.5 million in development and regulatory milestones for the initial indication, and up to $65 million in commercial milestones.
HekaBio led the regulatory approval process in Japan and will be responsible for launching and commercializing Alpha DaRT in the Japanese market.
Terms: Not explicitly disclosed.